Crossroads Neurovascular’s Path Balloon Guide Catheter Evaluated in Limited Market Release

October 15, 2025—Crossroads Neurovascular Inc. announced findings from the early clinical experience of the Path balloon guide catheter (BGC) during its ongoing limited market release (LMR) phase. The Path BGC is a 7-F guide catheter engineered for trackability, stability, and distal access. It is designed for both transradial and transfemoral approaches, stated the company.

In June, Crossroads Neurovascular announced FDA 510(k) clearance of the device for neurovascular interventions. The company advised that it is continuing to expand the LMR phase and anticipates broader availability of the Path BGC in the coming months.

According to the company, the 40 neurovascular procedures that were performed across four hospitals by eight experienced operators demonstrated the device’s versatility across a wide range of complex interventions.

Crossroads Neurovascular reported that the early procedures included aneurysm embolization (balloon-assisted coiling, flow diversion, and endovascular flow diversion); carotid stenting; middle meningeal artery embolization; mechanical thrombectomy; transverse sinus stenting; and arteriovenous malformation embolization. The procedures were performed via both transradial and transfemoral access, depending on the physician’s preference.

As summarized in the company’s press release, the early experience demonstrated 100% successful target vessel catheterization; superior stability in the aortic arch that provided excellent support and control during navigation and device delivery; and no device failures or device-related adverse events.

Additionally, the company noted that frequent elimination of intermediate catheters was enabled by the Path BGC’s ability to achieve distal access with ease while maintaining strong proximal support. The device’s extended catheter tips enabled safe and controlled tracking to more distal segments of the parent vessel, optimizing access during complex neurovascular interventions.

This early experience highlights the Path BGC’s versatility and performance across diverse and technically challenging neurovascular procedures, including 15 interventions involving highly tortuous vascular anatomy, stated the company.